For U.S. Healthcare Professionals Only

Instructions for Use:

75 mg Pen 150 mg Pen

Access & Affordability

PRALUENT: Available at a 60% lower list price

The lower list price is expected to help reduce PRALUENT out-of-pocket costs for many patients, especially those on Medicare.

  • Most Medicare patients can expect to pay between $25 and $150 per month*
  • Eligible commercial patients may still access the PRALUENT copay offer, which may reduce the copay to $0 (restrictions apply)

*Subject to plan adoption and tier placement determination.
†Eligible patients with commercial insurance not funded through a government healthcare program such as Medicare, Medicaid, or TRICARE subject to program terms and restrictions.

ACCESSIBILITY

Simplified prior authorization
process for some plans1

AFFORDABILITY

NDCs with a
60% lower list price2

FLEXIBILITY

Only PCSK9i that offers
2 powerful dosing options 3‡

‡Based on patient’s efficacy needs.

DOSING INFORMATION

  • The recommended starting dose of PRALUENT is 75 mg once every 2 weeks administered subcutaneously or alternatively 300 mg once every 4 weeks (monthly) for patients who prefer less frequent dosing. The majority of patients achieve sufficient LDL-C reduction with the 75 mg dosage. If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every 2 weeks

FREQUENTLY ASKED QUESTIONS

Expand All | Collapse All

Sanofi and Regeneron recognize that out-of-pocket costs for PRALUENT are a very important consideration for both patients and healthcare providers. This is why we have introduced the 60% lower list price National Drug Codes (NDCs). Based on this lower list price, Medicare patients are expected to pay between $25 to $150 per month in out-of-pocket costs (subject to plan adoption and tier placement). Eligible commercially-insured patients still have access to the PRALUENT copay offer, which may allow them to pay as little as a $0 copay (restrictions apply). You can refer patients to the MyPRALUENT offerings. Find out more information here or call 1-844-772-5836 - Option 1.

No, you can continue prescribing PRALUENT as you currently are for your appropriate patients. However, the lower priced PRALUENT NDC options might be a more appropriate option for some of your patients. You can continue to prescribe PRALUENT (75 mg or 150 mg) as you currently are and the pharmacist will determine which NDC to dispense based on your patient’s coverage.

The lower list price NDCs for PRALUENT 75 mg and 150 mg are the same formulation, same device, and same dosing regimens that you are already familiar with.

  • You can continue to prescribe PRALUENT as you currently do. The pharmacists should determine which NDC to dispense according to the individual patient’s coverage
  • Only the product name and dose will be in the EHR. The pharmacy will see the two NDCs for each dose and they will choose the appropriate one to fill

Yes, pharmacies have been notified and are able to order the lower list price NDCs.

No, you can continue to prescribe PRALUENT for your appropriate patients in the same manner you always have, regardless of whether it is through MyPRALUENT, a specialty pharmacy, or a retail pharmacy.

GET HELP WITH COVERAGE

Contact a Reimbursement Specialist for on-demand assistance

PATIENT SUPPORT & RESOURCES

Download resources to help get your patients started on PRALUENT

Download resources to help get your patients started on PRALUENT

HELP KEEP PATIENTS ON TRACK

Learn how MyPRALUENT® Patient Support can assist your patients

Learn how MyPRALUENT® Patient Support can assist your patients

INDICATIONS AND USAGE

PRALUENT is indicated:

  • to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
  • as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C).
IMPORTANT SAFETY INFORMATION
  • PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization.
  • Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve.
  • The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia (including heterozygous familial hypercholesterolemia (HeFH)) (≥5% of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza.
  • The most commonly occurring adverse reactions in the cardiovascular outcomes trial (>5% of patients treated with PRALUENT and occurring more frequently than placebo) were non-cardiac chest pain, nasopharyngitis, and myalgia.
  • In the primary hyperlipidemia (including HeFH) clinical trials, local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo.
  • The once-monthly (Q4W) 300mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively) in a trial in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind. The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms.
  • In a cardiovascular outcomes trial, local injection site reactions were reported in 3.8% of patients treated with PRALUENT versus 2.1% patients treated with placebo, and led to permanent discontinuation in 0.3% of patients versus <0.1% of patients, respectively.
  • In the primary hyperlipidemia trials, liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo.
  • In the primary hyperlipidemia trials, the most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus <0.1%).
  • PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT.

*

Back to the top ▲
References:
  1. Data on file. ESI communication. Sanofi and Regeneron. May 2018.
  2. Data on file. Price calculation. Sanofi and Regeneron. January 2019.
  3. PRALUENT® (alirocumab) Prescribing Information. Sanofi and Regeneron Pharmaceuticals.

© 2019 Sanofi US and Regeneron Pharmaceuticals, Inc.  All rights reserved.

Legal Disclaimer Information | Privacy Policy

Questions or Comments? Click here to contact Sanofi US or call 1-877-734-6777 to contact Regeneron Pharmaceuticals, Inc.
This site is intended for U.S. Healthcare Professionals Only.

SAUS.PRL.19.02.1357f(2) Last Update: October 2019

Sanofi US is hosting this website on behalf of Sanofi and Regeneron Pharmaceuticals, Inc.

IMPORTANT SAFETY INFORMATION
  • PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization
  • Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve